Mariner’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.2M | Buy |
268,901
+94,617
| +54% | +$5.52M | 0.02% | 566 |
|
|
2025
Q4 | $10.4M | Buy |
174,284
+74,056
| +74% | +$4.03M | 0.01% | 695 |
|
|
2025
Q3 | $5.43M | Buy |
100,228
+41,097
| +70% | +$2.35M | 0.01% | 890 |
|
|
2025
Q2 | $3.25M | Buy |
59,131
+25,476
| +76% | +$1.5M | ﹤0.01% | 1062 |
|
|
2025
Q1 | $2.38M | Buy |
33,655
+6,378
| +23% | +$429K | ﹤0.01% | 1147 |
|
|
2024
Q4 | $1.79M | Buy |
27,277
+10,527
| +63% | +$705K | ﹤0.01% | 1276 |
|
|
2024
Q3 | $1.18M | Sell |
16,750
-5,430
| -24% | -$454K | ﹤0.01% | 1483 |
|
|
2024
Q2 | $1.83M | Sell |
22,180
-2,542
| -10% | -$212K | ﹤0.01% | 1157 |
|
|
2024
Q1 | $2.16M | Sell |
24,722
-2,748
| -10% | -$246K | ﹤0.01% | 1069 |
|
|
2023
Q4 | $2.65M | Sell |
27,470
-21
| -0.1% | -$1.86K | 0.01% | 934 |
|
|
2023
Q3 | $2.43M | Buy |
27,491
+2,336
| +9% | +$208K | 0.01% | 898 |
|
|
2023
Q2 | $2.18M | Buy |
25,155
+2,321
| +10% | +$218K | 0.01% | 935 |
|
|
2023
Q1 | $2.22M | Sell |
22,834
-2,365
| -9% | -$245K | 0.01% | 912 |
|
|
2022
Q4 | $2.61M | Sell |
25,199
-303
| -1% | -$28.4K | 0.01% | 818 |
|
|
2022
Q3 | $2.16M | Buy |
25,502
+58
| +0.2% | +$5.16K | 0.01% | 740 |
|
|
2022
Q2 | $2.11M | Buy |
25,444
+1,384
| +6% | +$110K | 0.01% | 694 |
|
|
2022
Q1 | $1.86M | Buy |
24,060
+4,313
| +22% | +$361K | 0.01% | 740 |
|
|
2021
Q4 | $1.75M | Buy |
19,747
+7,168
| +57% | +$591K | 0.01% | 688 |
|
|
2021
Q3 | $972K | Sell |
12,579
-3,398
| -21% | -$268K | 0.01% | 709 |
|
|
2021
Q2 | $1.33M | Sell |
15,977
-701
| -4% | -$55.6K | 0.01% | 596 |
|
|
2021
Q1 | $1.26M | Sell |
16,678
-8,629
| -34% | -$705K | 0.01% | 559 |
|
|
2020
Q4 | $2.22M | Buy |
25,307
+9,919
| +64% | +$786K | 0.02% | 416 |
|
|
2020
Q3 | $1.17M | Buy |
15,388
+7
| +0% | +$708 | 0.01% | 471 |
|
|
2020
Q2 | $1.9M | Buy |
15,381
+429
| +3% | +$42.6K | 0.02% | 386 |
|
|
2020
Q1 | $1.26M | Sell |
14,952
-2,623
| -15% | -$226K | 0.02% | 440 |
|
|
2019
Q4 | $1.49M | Buy |
17,575
+649
| +4% | +$49K | 0.02% | 436 |
|
|
2019
Q3 | $1.14M | Buy |
16,926
+2,223
| +15% | +$171K | 0.01% | 455 |
|
|
2019
Q2 | $1.26M | Buy |
14,703
+2,176
| +17% | +$186K | 0.02% | 486 |
|
|
2019
Q1 | $1.11M | Buy |
12,527
+8
| +0.1% | +$741 | 0.02% | 469 |
|
|
2018
Q4 | $1.07M | Buy |
12,519
+100
| +0.8% | +$9.51K | 0.02% | 422 |
|
|
2018
Q3 | $1.2M | Sell |
12,419
-400
| -3% | -$39.9K | 0.03% | 369 |
|
|
2018
Q2 | $1.21M | Buy |
12,819
+1,042
| +9% | +$91.3K | 0.03% | 365 |
|
|
2018
Q1 | $955K | Sell |
11,777
-755
| -6% | -$64.8K | 0.03% | 320 |
|
|
2017
Q4 | $1.12M | Buy |
+12,532
| New | +$1.09M | 0.04% | 271 |
|
Other funds holding BMRN
VCM
VPM
Mariner's BMRN Position: Q1 2026 in Review
Mariner increased its BioMarin Pharmaceuticals (BMRN) stake by 54% in Q1 2026, buying an estimated $5.52M and bringing the position to 268,901 shares worth $15.2M. The position accounts for 0.02% of the portfolio, ranked #566.
Mariner first reported a position in BMRN in Q4 2017 and has held it in 34 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Mariner held 268,901 shares of BioMarin Pharmaceuticals worth $15.2M as of Q1 2026.
- Mariner bought 94,617 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $5.52M.
- BioMarin Pharmaceuticals made up 0.02% of Mariner's portfolio in Q1 2026, its #566 holding.
- Mariner first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.